Danaher resumed with an Outperform at RBC Capital

RBC Capital resumed coverage of Danaher (DHR) with an Outperform rating and $200 price target The firm sees the company’s growth recovering with the bioprocess market improving. A sustained bioprocess rebound, the lapping of “idiosyncratic headwinds,” and end market improvement put Danaher’s 6% revenue growth target within reach for 2027, the analyst tells investors in a research note.